- +1 858 909 0079
- +1 858 909 0057
- [email protected]
- +1 858 909 0079
- [email protected]
Cat# | Products (Recombinant protein) | Swiss Prot# | Size | Price (US$) | Order |
PP1030 | Recombinant Protein-Treponema vincentii 34 kDa membrane antigen (a.a.20 to 207) | C8PTE1 | 100 µg | 1195 | |
PP1031 | Recombinant Protein-Treponema vincentii antigen protein (a.a.20 to 320) | C8PMD0 | 100 µg | 1195 | |
PP1032 | Recombinant Protein-Treponema vincentii surface antigen (a.a.36 to 165) | C8PLU4 | 100 µg | 1195 | |
PP1033 | Recombinant Protein-Treponema vincentii Surface antigen BspA (a.a.39 to 377) | C8PRK7 | 100 µg | 1195 | |
RPP1030 | cDNA-Treponema vincentii 34 kDa membrane antigen (a.a.20 to 207) | C8PTE1 | 2 µg | 935 | |
RPP1031 | cDNA-Treponema vincentii antigen protein (a.a.20 to 320) | C8PMD0 | 2 µg | 1500 | |
RPP1032 | cDNA-Treponema vincentii surface antigen (a.a.36 to 165) | C8PLU4 | 2 µg | 800 | |
RPP1033 | cDNA-Treponema vincentii Surface antigen BspA (a.a.39 to 377) | C8PRK7 | 2 µg | 1690 |
Treponema vincentii cDNA and recombinant antigen
Treponema vincentii is a bacterium that is often associated with periodontal disease and other oral infections. This bacterium produces several antigens, which are proteins that can trigger an immune response in the body.
One of the key antigens produced by T. vincentii is a 34 kDa membrane antigen. This protein is located in the outer membrane of the bacterium and is considered to be a major antigen. It is often used in diagnostic tests to detect T. vincentii infections.
Another important antigen produced by T. vincentii is the surface antigen, also known as BspA. This antigen plays a critical role in the bacterium’s ability to adhere to and invade host cells. As such, it is considered to be a potential target for developing diagnostic tools and treatments for T. vincentii infections.
In addition to these antigens, T. vincentii also produces an antigen protein, although less information is available about this protein and its role in infection.
Overall, understanding the antigens produced by T. vincentii is important for developing effective diagnostic and treatment strategies for infections caused by this bacterium.
The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.
Treponema vincentii cDNA and recombinant antigen can be applied in various research and medical fields. In research, they can be used to study the molecular biology of T. vincentii, as well as its genome and gene expression. They can also be used to generate gene libraries for comparative genomics or for construction of genetic markers.
In medical applications, these molecules can be used to develop diagnostic tests for the detection of T. vincentii infection. They can also be used to develop recombinant vaccines and therapies to treat T. vincentii infections. Additionally, they can be used to study the epidemiology of the organism, as well as its pathogenesis and host-pathogen interactions.
Get the Latest News and Updates by Email
6393 Nancy Ridge Dr. Suite A
San Diego, CA 92121 USA
Fax: +1-858-909-0057
Get the Latest News and Updates by Email
© 2023 Bioclone Inc. All Rights Reserved.
Magnetic Beads Make Things Simple